Company Profile
China State Construction International Holdings Limited, an investment holding company, engages in the construction business for private and public sectors in Hong Kong, Chinese mainland, Macau, and internationally. It invests in and constructs toll roads and bridges, houses, buildings, hospitals, and schools. The company also undertakes civil engineering projects; operation of infrastructure assets; and mechanical and electrical engineering works. In addition, it is involved in undertaking foundation engineering works, general contracting and prefabricated construction, and industrial plant reconstruction activities; road contracts, and investment-driven contracting and other construction related investment businesses. Further, the company provides insurance brokerage, building construction, project and construction management, and installation repairs and maintenance services; curtain wall; sells and distributes construction materials; issues guaranteed notes; holds trademarks; insurance contracts and rental income from investment properties; leases plant and machinery; generates and supplies heat and electricity; manufactures building-integrated photovoltaics curtain walls and other related products; and manufactures and sells precast structures. Additionally, it engages in the marine engineering works, and property investment and management activities; and infrastructure project investments, infrastructure construction and operation, thermoelectricity, toll road operation, industrial plant reconstruction, project consultancy services, and facade contracting businesses. The company was founded in 1979 and is headquartered in Wan Chai, Hong Kong. China State Construction International Holdings Limited is a subsidiary of China Overseas Holdings Limited.
Latest News
Spain cereals firm Haricaman gets investment
AfDB approves $114m loan for Morocco battery plant
JD.com signs home comfort retail agreement with Carrier
If You Invest $10,000 in AGNC Investment Today, Here's the Monthly Passive Income You Could Have in 20 Years
IDEAYA Biosciences Advances IDE892 Into Phase 1/2 Monotherapy Expansion
| Sector | Industrials |
| Industry | Engineering & Construction |
| Website | https://www.csci.com.hk |
| Audit Risk | 5 |
| Board Risk | 3 |
| Overall Risk | 3 |
| Market Cap | 43.31B |
| Trailing P/E | 4.32 |
| Forward P/E | 3.98 |
| Dividend Rate | 0.57 |
| Dividend Yield | 6.96% |
| Trailing Annual Div. Rate | 0.56 |
| Trailing Annual Div. Yield | 6.86% |
| Trailing EPS | 1.9 |
| Forward EPS | 2.06 |
| Book Value | 15.43 |
| Price-to-Book | 0.53 |
| Enterprise-to-Revenue | 1.01 |
| Enterprise-to-EBITDA | 7.23 |
| Ex-Dividend Date | 06/17/2026 |
| Earnings Date | 08/20/2026 |
| Earnings Call Date |